These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases. Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126 [TBL] [Abstract][Full Text] [Related]
27. The Predictive Value of CD3+/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer. Liu J; Li J; Luo F; Wu S; Li B; Liu K Curr Oncol; 2023 Oct; 30(11):9647-9659. PubMed ID: 37999119 [TBL] [Abstract][Full Text] [Related]
28. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival. Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015 [TBL] [Abstract][Full Text] [Related]
29. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma. Hu C; Tian S; Lin L; Zhang J; Ding H Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855 [TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043 [TBL] [Abstract][Full Text] [Related]
31. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers. Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263 [TBL] [Abstract][Full Text] [Related]
32. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673 [TBL] [Abstract][Full Text] [Related]
33. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma. Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367 [TBL] [Abstract][Full Text] [Related]
34. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794 [TBL] [Abstract][Full Text] [Related]
35. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression. Pereira MA; de Castria TB; Ramos MFKP; Dias AR; Cardili L; de Moraes RDR; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES J Surg Oncol; 2021 Dec; 124(7):1040-1050. PubMed ID: 34255356 [TBL] [Abstract][Full Text] [Related]
36. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer. Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305 [TBL] [Abstract][Full Text] [Related]
37. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis. Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388 [TBL] [Abstract][Full Text] [Related]
38. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523 [TBL] [Abstract][Full Text] [Related]
39. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602 [TBL] [Abstract][Full Text] [Related]
40. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma. Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]